Patents by Inventor Pu-Ting Dong

Pu-Ting Dong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230256261
    Abstract: Methods of the present invention comprise photoinactivation of catalase in combination with low-concentration peroxide solutions and/or ROS generating agents to provide antibacterial effects.
    Type: Application
    Filed: April 20, 2023
    Publication date: August 17, 2023
    Inventors: Pu-Ting Dong, Jie Hui, Ji-Xin Cheng, Yifan Zhu
  • Patent number: 11633622
    Abstract: Methods of the present invention comprise photoinactivation of catalase in combination with low-concentration peroxide solutions and/or ROS generating agents to provide antibacterial effects.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: April 25, 2023
    Assignee: Pulsethera, Inc.
    Inventors: Pu-Ting Dong, Jie Hui, Ji-Xin Cheng, Yifan Zhu
  • Publication number: 20220184411
    Abstract: Methods of the present invention comprise photoinactivation of catalase in combination with low-concentration peroxide solutions and/or ROS generating agents to provide antibacterial effects.
    Type: Application
    Filed: March 3, 2022
    Publication date: June 16, 2022
    Inventors: Pu-Ting Dong, Jie Hui, Ji-Xin Cheng, Yifan Zhu
  • Patent number: 11298563
    Abstract: Methods of the present invention comprise photoinactivation of catalase in combination with low-concentration peroxide solutions and/or ROS generating agents to provide antibacterial effects.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: April 12, 2022
    Assignee: Pulsethera, Inc.
    Inventors: Pu-Ting Dong, Jie Hui, Ji-Xin Cheng, Yifan Zhu
  • Publication number: 20210353955
    Abstract: Methods of the present invention comprise photoinactivation of catalase in combination with low-concentration peroxide solutions and/or ROS generating agents to provide antibacterial effects.
    Type: Application
    Filed: July 28, 2021
    Publication date: November 18, 2021
    Inventors: Pu-Ting Dong, Jie Hui, Ji-Xin Cheng, Yifan Zhu
  • Patent number: 11110296
    Abstract: Methods of the present invention comprise photoinactivation of catalase in combination with low-concentration peroxide solutions and/or ROS generating agents to provide antibacterial effects.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: September 7, 2021
    Assignee: PULSETHERA, INC.
    Inventors: Pu-Ting Dong, Jie Hui, Ji-Xin Cheng, Yifan Zhu
  • Patent number: 11013933
    Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) possesses array of strategies to evade antibiotics through mutational inactivation, hiding inside host immune cells or concealing inside the biofilm in a sessile form. We report a drug-free approach to eradicate MRSA through blue-light bleaching of staphyloxanthin (STX), an anti-oxidative carotenoid residing inside the cell membrane of S. aureus. The photobleaching process, uncovered through a transient absorption imaging study and quantitated by mass spectrometry, decomposes STX and sensitizes MRSA to reactive oxygen species attack. Consequently, photobleaching using low-level blue light exhibits high-level synergy when combined with low-concentration of hydrogen peroxide. Antimicrobial effectiveness of this synergistic therapy is validated in MRSA culture, MRSA-infected macrophage cells, biofilm, and a mouse wound infection model. Collectively, these findings highlight broad applications of STX photobleaching for MRSA-infected diseases.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: May 25, 2021
    Assignee: Purdue Research Foundation
    Inventors: Ji-Xin Cheng, Mohamed Seleem, Pu-Ting Dong, Jie Hui
  • Publication number: 20210060351
    Abstract: Methods of the present invention comprise photoinactivation of catalase in combination with low-concentration peroxide solutions and/or ROS generating agents to provide antibacterial effects.
    Type: Application
    Filed: August 28, 2020
    Publication date: March 4, 2021
    Applicants: THE GENERAL HOSPITAL CORPORATION, PULSETHERA CORPORATION
    Inventors: Pu-Ting DONG, Jie HUI, Ji-Xin CHENG, Yifan ZHU, Michael K. MANSOUR
  • Publication number: 20200306295
    Abstract: Confronted with the rapid evolution and dissemination of antibiotic resistance, there is an urgent need to develop alternative treatment strategies for drug-resistant S. aureus, especially for methicillin-resistant S. aureus (MRSA). We report a photonic approach to eradicate MRSA through blue-light photolysis of staphyloxanthin (STX), an anti-oxidative carotenoid acting as the constituent lipid of the functional membrane microdomains of S. aureus. Our transient absorption imaging study and mass spectrometry unveil the photolysis process of STX. After effective STX photolysis by pulsed laser, cell membranes are found severely disorganized and malfunctioned to defense antibiotics, as unveiled by membrane permeabilization, membrane fluidification, and detachment of membrane protein, PBP2a.
    Type: Application
    Filed: September 24, 2019
    Publication date: October 1, 2020
    Applicant: Purdue Research Foundation
    Inventors: Ji-xin Cheng, Mohamed Seleem, Pu-Ting Dong, Jie Hui
  • Publication number: 20190126063
    Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) possesses array of strategies to evade antibiotics through mutational inactivation, hiding inside host immune cells or concealing inside the biofilm in a sessile form. We report a drug-free approach to eradicate MRSA through blue-light bleaching of staphyloxanthin (STX), an anti-oxidative carotenoid residing inside the cell membrane of S. aureus. The photobleaching process, uncovered through a transient absorption imaging study and quantitated by mass spectrometry, decomposes STX and sensitizes MRSA to reactive oxygen species attack. Consequently, photobleaching using low-level blue light exhibits high-level synergy when combined with low-concentration of hydrogen peroxide. Antimicrobial effectiveness of this synergistic therapy is validated in MRSA culture, MRSA-infected macrophage cells, biofilm, and a mouse wound infection model. Collectively, these findings highlight broad applications of STX photobleaching for MRSA-infected diseases.
    Type: Application
    Filed: September 24, 2018
    Publication date: May 2, 2019
    Applicant: Purdue Research Foundation
    Inventors: Ji-xin Cheng, Mohamed Seleem, Pu-Ting Dong, Jie Hui